AGENDA DAY 2
Day 2 Antibody Congress
10:21
SPEED NETWORKING
MORNING REFRESHMENTS
Bispecifics
11:21
A novel bispecific antibody that targets soluble antigen to the liver for clearance using an Fc gamma related mechanism
11:41
Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system
- Bispecific antibodies have gained increased relevance in research and therapeutic settings despite the complexities in their production and challenges in finding the right combination.
- The presentation will discuss strategies and consideration to screen for the best bispecific antibody pair.
- In addition, a novel approach to produce a bispecific antibody with natural architecture in a single cell will be discussed. The technology now simplifies bispecific production for research and development.
12:01
ADAPTIR™ Bispecifics, a novel platform for development of immuno-oncology therapeutics
- Key features and differentiating aspects of the ADAPTIR™ bispecific platform, including new preclinical in vivo and in vitro activity, pharmacokinetic and manufacturability data.
- ADAPTIR™ bispecific proteins offer advantages over other formats, derived from the flexible and modular nature of the ADAPTIR™ structure.
- Potent biological activity can be achieved, while retaining traditional antibody-like manufacturing characteristics.
- One ADAPTIR™ molecule is currently undergoing clinical trials, with several more bispecific immunotherapies in preclinical development.
LUNCH
14:20
Armed antibodies and ADCs
14:21
Assays for quantitation of unconjugated and conjugated payloads
- ADC analytes and analytical methods; LCMS method for un-conjugated Calicheamicin; Hybrid LCMS methods for conjugated Calicheamicin
- MyeChild 01 pediatric clinical trials and selection of PK assays
- Challenges with unconjugated Calicheamicin assay validation
- Dual-Analyte assay for Mylotarg PK in clinical and preclinical studies
14:41
Bioanalytical strategies for measuring critical and relevant analytes of ADCs
- ADCs exhibit unique PK and pharmacological properties because they are a hybrid between mAb and small molecule conjugated by a linker
- Three distinct components (mAb, linker, payload) need to be optimized within the context of ADC overall stability and potency
- Crucial work needs to be done to enhance understanding of PK/PD for ADCs
Mehran Moghaddam, Head of DMPK, Celgene
15:01
Immunogenetics and structural biology of cow ultralong CDR3 Antibodies
Dr Vaughn Smider, Assistant Professor of Molecular Biology Department of Cell and Molecular Biology, The Scripps Research Institute
AFTERNOON REFRESHMENTS
15:59
Commercial Targets
16:01
Quantitative antibody response to public health-focused vaccines
- Sequential immunization strategies for HIV and analysis across mutations
- Measuring and characterizing Ebola vaccine response 7-day post immunization
- Deconvolution of human responses to Zika virus
16:21
Clinical update: targeting DLL4 and Notch 2/3 to inhibit tumors
- An update on OncoMed’s clinical development of antibodies targeting DLL4 and Notch2/3
- Blocking DLL4 has been shown in preclinical studies to result in anti-tumor activity via multiple mechanisms, including inhibiting cancer stem cell growth and promoting cell differentiation, disrupting angiogenesis and potentially enhancing anti-tumor immune response.
- Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab has been shown in preclinical models to inhibit cancer stem cell growth, and promote cell differentiation, as well as disrupt tumor angiogenesis by inhibiting vascular pericytes.
16:41
Production of novel Ab fragments against Celiac’s disease
- Inflammatory processes in Celiac’s Disease are in response to dietary gluten and related prolamins uptake
- Novel bivalent tandem single chain Fragment variable (scFv) in E. coli to act as a neutralizing agent during dietary gluten uptake
- Establishing a comprehensive downstream process, consisting of cell disruption, IB wash, solubilization, refolding and product purification to reduce inclusion body effect in e.coli
End of conference
last published: 18/May/17 16:05 GMT
Organiser
